ECCO 2022 Archives - Medical Conferences

Letter from the Editor

Editor

Dr Marjolijn Duijvestein, Radboudumc, the Netherlands

Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

ECCO 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Guselkumab shows encouraging safety and efficacy in ulcerative colitis

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Mirikizumab efficacious for active ulcerative colitis

Presented By

Prof. Geert D’Haens, Amsterdam University Medical Center, the Netherlands

Risankizumab more efficacious in colonic than in ileal Crohn’s disease

Presented By

Dr Peter Bossuyt, Imelda General Hospital, Belgium

Guselkumab plus golimumab promising combination for ulcerative colitis

Presented By

Prof. Bruce Sands, Mount Sinai School of Medicine, NY, USA

Combined endpoint may support personalised medicine in ulcerative colitis

Presented By

Prof. Stefan Schreiber, Christian-Albrecht University, Germany

Filgotinib seems promising for perianal fistulising Crohn’s disease

Presented By

Dr Walter Reinisch, Medical University of Vienna, Austria

Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Upadacitinib counters extraintestinal manifestations in ulcerative colitis

Presented By

Prof. Jean-Frédéric Colombel, Icahn School of Medicine at Mount Sinai, NY, USA

Upadacitinib effector pathways unravelled

Presented By

Dr Bram Verstockt, KU Leuven, Belgium

Deucravacitinib does not meet primary endpoint for ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By

Dr Neeraj Narula, McMaster University, Canada

Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis

Presented By

Prof. Remo Panaccione , University of Calgary, Canada

Subcutaneous infliximab versus subcutaneous vedolizumab in IBD

Presented By

Prof. Laurent Peyrin-Biroulet, Nancy University Hospital, France

Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis

Presented By

Dr Bernd Bokemeyer, University Hospital Schleswig-Holstein, Germany

Ozanimod treatment shows maintained response in ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease

Presented By

Prof. Edouard Louis, University Hospital Liège, Belgium

Vedolizumab first approved therapy for chronic pouchitis

Presented By

Prof. Simon Travis, University of Oxford, UK

VEDOKIDS: Vedolizumab seems effective in paediatric IBD

Presented By

Dr Dan Turner, Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Israel

Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met

Presented By

Dr Marie Truyens, Ghent University Hospital, Belgium

Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy

Presented By

Dr Kristin Jørgensen, Akershus University Hospital, Norway

Segmental colectomy beneficial over total colectomy in Chrohn’s disease

Presented By

Dr Gianluca Pellino, University of Campania Luigi Vanvitelli, Italy

Modified 2-stage ileal pouch-anal anastomosis versus 3-stage alternative

Presented By

Dr Stefan Holubar, Cleveland Clinic Foundation, OH, USA

Similar results for different corticosteroid tapering protocols in UC

Presented By

Ms Pernille Ovesen, Herlev University Hospital, Denmark

Lessons from the COVID-19 pandemic for IBD management

Presented By

Prof. Siew Ng, Chinese University of Hong Kong, Hong Kong

AI model distinguishes between histologic activity and remission in ulcerative colitis

Presented By

Dr Tommaso Parigi, Humanitas University, Italy

Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors

Presented By

Dr Yael Haberman, Sheba Medical Center, Israel

Novel classification system for perianal fistulising Crohn’s disease

Presented By

Dr Philip Tozer, St Mark’s Hospital and Academic Institute, UK

Vaccination tool associated with improved vaccination coverage in IBD

Presented By

Ms Liselotte Fierens, KU Leuven, Belgium

Comparable safety profiles of biological therapies in elderly patients with IBD

Presented By

Dr Gustavo Drügg Hahn, McGill University Health Center, Canada

Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease

Presented By

Prof. Shomron Ben-Horin, Tel-Aviv University, Israel

RESTORE-UC: No better outcomes with FMT superdonors than with autologous stools

Presented By

Dr Clara Caenepeel, KU Leuven, Belgium

Table of Contents

Featured articles

Novel Treatment Modalities

Head-to-Head Comparisons

Short-Term and Long-Term Treatment Results

Specific Therapeutic Strategies

Miscellaneous Topics